Abstract 166P
Background
Gallbladder (GB) cancer shows high prevalence in South Korea, and tends to show high fatality. In surgically fit patients, radical resection aiming an R0 margin combined with lymphadenectomy is the mainstay of curative-intent therapy. In spite of R0 resection, however, high recurrence rate is observed in GB cancer, demanding a need to figure out risk factors related to recurrence after surgery.
Methods
This is a single center, retrospective cohort study conducted on 148 patients with GB cancer who underwent R0 resection between January 1st, 2014 and December 31st, 2019. Several variables were analyzed with statistical tools to identify risk factors related to prognosis. Early recurrence, defined as progression of disease within one year after R0 resection, was studied with logistic regression analysis.
Results
Early recurrence was observed in 15.5% (N=23) of patients. Based on statistical analysis, independent risk factors of early recurrence were age over 65 (hazard ratio [HR] 4.44, 95% confidence interval [CI] 1.25 - 15.75, p=0.021), glycated hemoglobin (HbA1c) level more than 6.5% (HR 5.00, 95% CI 1.37 – 18.31, p=0.015), surgical T stage more than T3 (HR 16.76, 95% CI 5.76 – 48.73, p<0.001), surgical N stage more than N1 (HR 5.82, 95% CI 2.22 – 15.28, p<0.001), pathologic differentiation of moderate to poor differentiation (HR 5.20, 95% CI 1.64 – 16.48, p=0.005), reversed albumin-globulin ratio (HR 0.08, 95% CI 0.01 – 0.45, p=0.004), high c-reactive protein (CRP) level (HR 1.22, 95% CI 1.08 – 1.38, p=0.001), and high carbohydrate antigen (CA) 19-9 level (HR 3.53, 95% CI 1.36 – 9.13, p=0.009). Table: 166P
Variable | Univariate analysis | ||
OR | 95% CI | P | |
Age (≥ 65 vs < 65) | 4.44 | (1.25 - 15.75) | .021 |
Sex (male vs female) | 0.86 | (0.34 - 2.17) | .743 |
Smoking (yes vs no) | 1.02 | (0.27 - 3.83) | .974 |
Alcohol (yes or no) | 0.76 | (0.24 - 2.44) | .649 |
HbA1C (≥ 6.5 vs < 6.5) | 5.00 | (1.37 - 18.31) | .015 |
Surgical T stage (T3 + T4 vs T1 + T2) | 16.76 | (5.76 - 48.73) | <.001 |
Surgical N stage (N1 + N2 vs N0) | 5.82 | (2.22 - 15.28) | <.001 |
Pathology differentiation (non-well vs well) | 5.20 | (1.64 - 16.48) | .005 |
WBC | 0.99 | (0.89 - 1.10) | .875 |
AST | 1.00 | (1.00 - 1.00) | .728 |
ALT | 1.00 | (1.00 - 1.01) | .653 |
Bilirubin | 1.05 | (0.90 - 1.23) | .549 |
Albumin-globulin ratio (≥ 1.0 vs < 1.0) | 0.08 | (0.01 - 0.45) | .004 |
CRP | 1.22 | (1.08 - 1.38) | .001 |
CA19-9 (≥ 39.0 vs < 39.0) | 3.53 | (1.36 - 9.13) | .009 |
Conclusions
Advanced pathologic stage and high inflammatory marker levels, reflecting high tumor burden, were related with poor surgical outcome. Interestingly, high HbA1c level was connected with early recurrence as well. In conclusion, active screening for early detection, reducing inflammatory conditions, and managing diabetes might reduce early recurrence after R0 resection of GB cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pusan National University Hospital.
Funding
This work was supported by clinical research grant from Pusan National University in 2023.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract